Viewing Study NCT00022932

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2026-06-02 @ 9:29 AM
Study NCT ID: NCT00022932
Status: UNKNOWN
Last Update Posted: 2005-06-24
First Post: 2001-08-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Sponsor: Corixa Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkin's Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Hodgkin's Lymphoma View
None Radioimmunotherapy View
None Monoclonal Antibody View
None Corixa View
None Bexxar View
None Anti-B1 Antibody View
None Tositumomab View
None Iodine -131 Anti-B1 Antibody View
None Iodine I 131 Tositumomab View